Skip to main content

FDA Approves Guerbet's Dotarem (gadoterate meglumine) for Pediatric Patients Younger Than Two Years

PRINCETON, N.J., Sept. 5, 2017 /PRNewswire/ -- Guerbet LLC USA, the US affiliate of the global specialist in contrast products and solutions for medical imaging, announced today that the US Food and Drug Administration (FDA) has approved Dotarem (gadoterate meglumine) for intravenous use with magnetic resonance imaging (MRI) in pediatric patients under two years old, including term neonates, to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system (CNS).

Dotarem was previously approved for this use in patient populations over the age of two.

This supplemental indication fulfills a post marketing requirement, acknowledged when Dotarem was first registered in March 2013, to strictly comply with the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c).

The FDA's review was based on a study showing that at the standard dose (0.1 mmol/kg),1 the pharmacokinetic (PK) and safety profiles in pediatric patients under two were similar to those of older children and adults.

The study enrolled 51 pediatric patients in nine centers, with ages spanning from term neonates to 23 months and with normal renal function. It evaluated 45 pediatric patients for PK profile and safety, including five subjects aged less than one month and nine subjects aged one to three months. It assessed efficacy in a subset of 28 subjects who underwent an MRI examination of brain, spine, and associated tissues.

In this pediatric population the observed safety profile of Dotarem was consistent with what has been reported in older populations. In one patient, rash was reported as a moderate adverse event. Serious AEs unrelated to Dotarem were reported in one out of 45 patients. Evaluation of images from contrast-enhanced MRI of the CNS supported extrapolation of CNS efficacy findings reported in adults and older children.

"It is critical for Guerbet to help patients and their healthcare providers meet this medical need. We are committed to providing safe and effective contrast media to improve diagnosis of all populations including those who need special care, like young children. In fact, a study published earlier this year in Pediatric Radiology found that 80% of children's hospitals surveyed now use macrocyclic contrast agents2," said Massimo Carrara, VP North America.

Dotarem is the only macrocyclic and ionic gadolinium-based contrast medium (a kind that provides high molecular stability) available in the US.

To date, Dotarem is approved in 79 countries worldwide. More than 65 million doses of Dotarem have been administered since first launch. No unconfounded cases of NSF have been reported for Dotarem.

Ref 1: Dotarem®(gadoterate meglumine) US Prescribing Information
Ref 2: Use of gadolinium-based magnetic resonance imaging contrast agents and awareness of brain gadolinium deposition among pediatric providers in North America.Pediatr Radiol. 2017 May;47(6):657-664.

About Guerbet

Guerbet is a pioneer in the contrast agent field with over 90 years' of experience and is one of the leaders in medical imaging worldwide. It offers a full range of pharmaceutical products, medical devices and services for X-ray (RX) and Magnetic Resonance Imaging (MRI) scanners and Interventional Radiology and Theranostics (IRT) to improve the diagnosis and treatment of patients. With 7% of its revenue and more than 200 employees dedicated to R&D, Guerbet invests heavily in research and innovation. Guerbet (GBT) is listed on Euronext Paris (Segment B – Mid Caps) and generated €776 million in revenue in 2016. For more information about Guerbet, visit www.guerbet.com

SOURCE Guerbet LLC USA

Posted: September 2017

Related articles

Dotarem (gadoterate meglumine) FDA Approval History

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.